| Molecular Formula | C13H10Cl2N2O4S |
| Molar Mass | 361.2 |
| Density | 1.566±0.06 g/cm3(Predicted) |
| Melting Point | 141-142℃ |
| Boling Point | 526.3±60.0 °C(Predicted) |
| Solubility | DMSO: soluble20mg/mL |
| Appearance | Yellow solid |
| Color | Tan |
| pKa | 5.83±0.10(Predicted) |
| Storage Condition | 2-8°C |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months. |
| In vitro study | FH535 is an inhibitor of Wnt/β-catenin and PPAR. FH535 inhibits PPARγ and PPARδ transactivation in HCT116 cells. FH535 (15 μM) activities depend on functional PPARδ but does not require a cysteine residue in the PPAR ligand-binding domain. FH535 inhibits recruitment of the coactivators GRIP1 and β-catenin to PPARδ and PPARγ. FH535 shows toxic effects on 12 carcinoma cell lines expressing wnt/β-catenin pathway. FH535 (20 μM) suppresses the β-catenin pathway in pancreatic cancer cells, and inhibits pancreatic cancer cell migration. Furthermore, FH535 (20, 40 μM) inhibits pancreatic cancer cell invasion and cell growth. FH535 represses angiogenesis-related genes in pancreatic cancer cells. |
| In vivo study | FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts. |
| Hazard Symbols | Xi - Irritant![]() |
| Risk Codes | 41 - Risk of serious damage to eyes |
| Safety Description | 36 - Wear suitable protective clothing. |
| WGK Germany | 3 |
| HS Code | 29350090 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.769 ml | 13.843 ml | 27.685 ml |
| 5 mM | 0.554 ml | 2.769 ml | 5.537 ml |
| 10 mM | 0.277 ml | 1.384 ml | 2.769 ml |
| 5 mM | 0.055 ml | 0.277 ml | 0.554 ml |
| biological activity | FH535 is an inhibitor of Wnt/β-catenin and PPAR and has anti-tumor activity. |
| target | PPAR Wnt β-catenin |
| in vitro study | FH535 is an inhibitor of Wnt/β-catenin and PPAR. FH535 inhibits PPARγ and PPARδ transactivation in HCT116 cells. FH535 (15 μM) activities dependent on functional PPARδ but does not require a cysteine residue in the PPAR ligand-binding domain. FH535 inhibits recruitment of the coactivators GRIP1 and β-catenin to PPAR δ and PPAR γ. FH535 shows effects on 12 carcinoma cell lines expressing wnt/β-catenin pathway. FH535 (20 μM) suppresses the β-catenin pathway in pancreatic cancer cells, and inhibits pancreatic cancer cell migration. Furthermore, FH535 (20, 40 μ M) inhibits pancreatic cancer cell invasion and cell growth. FH535 represses angiogenesis-related genes in pancreatic cancer cells. |
| in vivo study | FH535 (25 mg/kg, I. p.) exhibits an anti-tumour effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts. |